FDA Urged To Articulate Policy On Clinical Decision Support Software
This article was originally published in The Gray Sheet
Executive Summary
The topic of clinical decision support software does not belong in FDA guidance on mobile health applications and should be addressed, as soon as possible, in separate guidance, stakeholders say.
You may also be interested in...
FDA Outlines Path For Guidance On Clinical Decision Support Tools
CDRH officials are looking for ways to better define when and how clinical decision support tools included in mobile health applications or medical software should face FDA regulation.
Industry Applauds FDA Draft Guidance On Mobile Medical Apps
The medical device and software industries voiced support last week for a July 19 FDA draft guidance that helps clarify the types of mobile software applications that would face FDA regulation.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.